September 2, 2021 -- BioLife Solutions has closed on its acquisition of Sexton Biotechnologies, a 2019 spinoff of Cook Regentec.
The acquisition is part of BioLife's strategy to assemble a portfolio of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, company representatives said.
Sexton's bioproduction portfolio includes proprietary closed vials for cell therapy final-dose packaging, human platelet lysate media, a bio-defined replacement for fetal bovine serum or human serum used in cell manufacturing, and automated cell processing machines. The company's products are currently embedded in more than 50 ongoing clinical trials of new cell and gene therapies, BioLife said.
This is BioLife's sixth acquisition in the last 2.5 years.
Copyright © 2021 scienceboard.net